JAZZ
NEUTRAL
$194.2
Live
Jazz Pharmaceuticals plc · NASDAQ
Target $223.71
(+15.2%)
$97.5
52W Range
$200.24
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$11.96B
P/E
N/A
ROE
-8.5%
Profit margin
-8.3%
Debt/Equity
1.26
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
JAZZ presents a stark contradiction between fundamental health and market valuation, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits an extremely attractive valuation with a Forward P/E of 7.74 and a PEG ratio of 0.63, its internal financial health is deteriorating, evidenced by negative profit margins and ROE. Despite a massive 1-year price surge of 90.3%, bearish insider sentiment and a low technical trend score suggest a potential peak or internal instability. The stock currently functions as a high-risk value play where analyst optimism clashes with poor deterministic health metrics.
Key Strengths
Exceptional Gross Margin of 91.67%
Highly attractive Forward P/E of 7.74
Undervalued PEG ratio of 0.63
Consistent double-digit revenue growth (10.10% YoY)
Strong analyst consensus with a target price of $223.71
Key Risks
Critically low Piotroski F-Score (2/9) indicating weak financial trends
Negative Profit Margin (-8.35%) and negative ROE (-8.47%)
Bearish insider activity with $15.3M in sales and zero buys
Weak technical trend score (10/100) despite recent price gains
Debt-to-Equity ratio of 1.26 suggests moderate leverage risk
AI Fair Value Estimate
Based on comprehensive analysis
$210.0
+8.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
50
Moderate
90
65
75
20
0
AI Verdict
Speculative Value
Key drivers: Deep valuation discount, Poor financial health scores, Strong revenue growth, Insider divestment
Confidence
90%
Value
90/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E 7.74 is significantly below sector averages
- PEG 0.63 suggests growth is not priced in
Watchpoints
- Price/Book of 2.76 is moderate
Future
65/100
Ref Growth rates
Positives
- 10.1% YoY Revenue growth
- Positive analyst target price
Watchpoints
- Sluggish earnings growth (3.2%)
Past
75/100
Ref Historical trends
Positives
- Impressive 1Y return of +90.3%
- Strong 6M momentum (+43.4%)
Watchpoints
- Inconsistent quarterly earnings surprises
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio 1.86 shows adequate short-term liquidity
Watchpoints
- Piotroski F-Score 2/9 is critically weak
- Negative profit margins and ROE
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$194.2
Analyst Target
$223.71
Upside/Downside
+15.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for JAZZ and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals plc
Primary
|
+19.7% | +32.4% | +90.3% | +43.4% | +4.7% | +3.9% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+121.6% | +109.3% | +65.7% | +16.2% | -2.4% | +2.3% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
IONS
Ionis Pharmaceuticals, Inc.
Peer
|
+83.9% | +101.9% | +181.4% | +7.4% | +0.5% | +0.5% |
JAZ
Jazz Pharmaceuticals plc
Primary
5Y
+19.7%
3Y
+32.4%
1Y
+90.3%
6M
+43.4%
1M
+4.7%
1W
+3.9%
ENS
The Ensign Group, Inc.
Peer
5Y
+121.6%
3Y
+109.3%
1Y
+65.7%
6M
+16.2%
1M
-2.4%
1W
+2.3%
EXE
Exelixis, Inc.
Peer
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
ION
Ionis Pharmaceuticals, Inc.
Peer
5Y
+83.9%
3Y
+101.9%
1Y
+181.4%
6M
+7.4%
1M
+0.5%
1W
+0.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
7.74
PEG Ratio
0.63
P/B Ratio
2.76
P/S Ratio
2.8
EV/Revenue
3.5
EV/EBITDA
8.71
Market Cap
$11.96B
Profitability
Profit margins and return metrics
Profit Margin
-8.34%
Operating Margin
27.06%
Gross Margin
91.67%
ROE
-8.47%
ROA
5.38%
Growth
Revenue and earnings growth rates
Revenue Growth
+10.1%
Earnings Growth
+3.2%
Q/Q Revenue Growth
+10.09%
Q/Q Earnings Growth
+6.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.26
Moderate
Current Ratio
1.86
Good
Quick Ratio
1.46
Good
Cash/Share
$39.67
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.2B
Gross Margin
87.2%
Op. Margin
21.2%
Net Margin
17.0%
Total Assets
$11.7B
Liabilities
$7.3B
Equity
$4.3B
Debt/Equity
1.70x
Operating CF
$0.4B
CapEx
$-0.1B
Free Cash Flow
$0.3B
FCF Yield
81%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$6.64
+2.0% surprise
2025-11-05
$8.13
+39.0% surprise
2025-08-05
$-8.25
-32.1% surprise
Healthcare Sector Comparison
Comparing JAZZ against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-8.47%
This Stock
vs
-46.09%
Sector Avg
-81.6%
(Below Avg)
Profit Margin
-8.34%
This Stock
vs
-19.58%
Sector Avg
-57.4%
(Weaker)
Debt to Equity
1.26
This Stock
vs
4.1
Sector Avg
-69.3%
(Less Debt)
Revenue Growth
10.1%
This Stock
vs
88.16%
Sector Avg
-88.5%
(Slower)
Current Ratio
1.86
This Stock
vs
3.58
Sector Avg
-48.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals plc
|
NEUTRAL | $11.96B | - | -8.5% | -8.3% | $194.2 | |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.96B | 34.36 | 16.9% | 6.8% | $204.79 | Compare |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
|
IONS
Ionis Pharmaceuticals, Inc.
|
BEARISH | $12.42B | - | -70.8% | -40.4% | $75.17 | Compare |
JAZZ
Jazz Pharmaceuticals plc
NEUTRAL
Mkt Cap
$12.0B
P/E
-
ROE
-8.5%
Price
$194.2
ENSG
The Ensign Group, Inc.
NEUTRAL
Mkt Cap
$12.0B
P/E
34.4
ROE
16.9%
Price
$204.79
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | COZADD BRUCE C | Director | Sale | 6,000 | $1,143,010 |
| 2026-03-09 | CARR PATRICIA | Officer | Sale | 1,287 | $235,444 |
| 2026-03-03 | COZADD BRUCE C | Director | Sale | 6,000 | $1,118,613 |
| 2026-02-27 | CARR PATRICIA | Officer | Sale | 2,370 | $456,466 |
| 2026-02-27 | RIEDEL NORBERT G | Director | Sale | 3,415 | $655,680 |
| 2026-02-27 | RIEDEL NORBERT G | Director | Option Exercise | 3,415 | $471,543 |
| 2026-02-26 | CARR PATRICIA | Officer | Stock Award | 2,223 | - |
| 2026-02-26 | PEARCE SAMANTHA | Officer | Stock Award | 9,782 | - |
| 2026-02-26 | HENDERSON MARY ELIZABETH | Officer | Stock Award | 4,447 | - |
| 2026-02-26 | HENDERSON MARY ELIZABETH | Officer | Sale | 5,343 | $1,039,134 |
| 2026-02-26 | JOHNSON PHILIP L | Chief Financial Officer | Stock Award | 11,857 | - |
| 2026-02-26 | GALA RENEE D | Chief Executive Officer | Stock Award | 44,465 | - |
| 2026-02-26 | LOVE TED WENDELL | Director | Stock Award | 1,527 | - |
| 2026-02-26 | IANNONE ROBERT | Officer | Stock Award | 14,822 | - |
| 2026-02-26 | PATIL NEENA M | Officer | Stock Award | 10,079 | - |
COZADD BRUCE C
Director
2026-04-01
6,000 shares
·
$1,143,010
CARR PATRICIA
Officer
2026-03-09
1,287 shares
·
$235,444
COZADD BRUCE C
Director
2026-03-03
6,000 shares
·
$1,118,613
CARR PATRICIA
Officer
2026-02-27
2,370 shares
·
$456,466
RIEDEL NORBERT G
Director
2026-02-27
3,415 shares
·
$655,680
RIEDEL NORBERT G
Director
2026-02-27
3,415 shares
·
$471,543
CARR PATRICIA
Officer
2026-02-26
2,223 shares
PEARCE SAMANTHA
Officer
2026-02-26
9,782 shares
HENDERSON MARY ELIZABETH
Officer
2026-02-26
4,447 shares
HENDERSON MARY ELIZABETH
Officer
2026-02-26
5,343 shares
·
$1,039,134
JOHNSON PHILIP L
Chief Financial Officer
2026-02-26
11,857 shares
GALA RENEE D
Chief Executive Officer
2026-02-26
44,465 shares
LOVE TED WENDELL
Director
2026-02-26
1,527 shares
IANNONE ROBERT
Officer
2026-02-26
14,822 shares
PATIL NEENA M
Officer
2026-02-26
10,079 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
17 analysts
Piper Sandler
2026-03-19
Overweight
Overweight
Barclays
2026-02-27
Overweight
RBC Capital
2026-02-25
Outperform
Outperform
Morgan Stanley
2026-02-25
Overweight
Overweight
Wells Fargo
2026-02-25
Overweight
Overweight
B of A Securities
2026-02-25
Buy
Buy
Truist Securities
2026-01-12
Buy
Buy
Needham
2026-01-12
Buy
Buy
Piper Sandler
2025-12-10
Overweight
Overweight
UBS
2025-11-24
Buy
Neutral
Past News Coverage
Recent headlines mentioning JAZZ from our newsroom.
Newest → oldest
No matching news yet.